NasdaqGM:RVNC

Stock Analysis Report

Executive Summary

Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications.

Rewards

Loading interface...

Risk Analysis

Loading interface...

Snowflake Analysis

Excellent balance sheet and slightly overvalued.

Share Price & News

How has Revance Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Information is not available.


Market Performance


7 Day Return

-18.6%

RVNC

1.1%

US Pharmaceuticals

0.3%

US Market


1 Year Return

-29.3%

RVNC

-0.07%

US Pharmaceuticals

18.5%

US Market

Information is not available.

Information is not available.


Shareholder returns

RVNCIndustryMarket
7 Day-18.6%1.1%0.3%
30 Day5.2%-1.7%1.5%
90 Day30.0%8.7%5.7%
1 Year-29.3%-29.3%2.5%-0.07%21.1%18.5%
3 Year1.0%1.0%31.5%22.1%45.9%36.4%
5 Year-0.2%-0.2%25.6%12.4%71.4%52.5%

Price Volatility Vs. Market

How volatile is Revance Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Revance Therapeutics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Information is not available.

Information is not available.


Price To Earnings Ratio

Information is not available.

Information is not available.


Price to Earnings Growth Ratio

Information is not available.


Price to Book Ratio

Information is not available.


Next Steps

Future Growth

How is Revance Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?

52.7%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Information is not available.

Information is not available.

Information is not available.

Information is not available.

Information is not available.


Earnings per Share Growth Forecasts


Future Return on Equity

Information is not available.


Next Steps

Past Performance

How has Revance Therapeutics performed over the past 5 years?

-21.5%

Historical annual earnings growth


Earnings and Revenue History

Information is not available.

Information is not available.


Past Earnings Growth Analysis

Information is not available.

Information is not available.

Information is not available.


Return on Equity

Information is not available.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Revance Therapeutics's financial position?


Financial Position Analysis

Information is not available.

Information is not available.


Debt to Equity History and Analysis

Information is not available.

Information is not available.

Information is not available.

Information is not available.


Balance Sheet

Information is not available.

Information is not available.


Next Steps

Dividend

What is Revance Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage2.7%forecastin3Years0%

Current dividend yield vs market & industry

Information is not available.

Information is not available.


Stability and Growth of Payments

Information is not available.

Information is not available.


Current Payout to Shareholders

Information is not available.


Future Payout to Shareholders

Information is not available.


Next Steps

Management

What is the CEO of Revance Therapeutics's salary, the management and board of directors tenure and is there insider trading?

1.6yrs

Average management tenure


CEO

Mark Foley (54yo)

0.2yrs

Tenure

US$243,007

Compensation

Mr. Mark J. Foley serves as President and Chief Executive Officer at Revance Therapeutics, Inc. since October 14, 2019. He served as the Managing Director of RWI Ventures from 2004 to 2018. Mr. Foley joine ...


Management Age and Tenure

1.6yrs

Average Tenure

49yo

Average Age

Information is not available.


Board Age and Tenure

4.1yrs

Average Tenure

61.5yo

Average Age

Information is not available.


Insider Trading

Information is not available.


Ownership Breakdown

Information is not available.


Management Team

  • Mark Foley (54yo)

    President

    • Tenure: 0.2yrs
    • Compensation: US$243.01k
  • Abhay Joshi (56yo)

    Chief Operating Officer

    • Tenure: 4yrs
    • Compensation: US$2.25m
  • Jeanie Herbert

    Senior Director of Investor Relations & Corporate Communications

    • Tenure: 3yrs
  • Dustin Sjuts

    Head of Commercial - Aesthetics & Therapeutics

    • Tenure: 1.1yrs
  • Roman Rubio (48yo)

    Senior Vice President of Clinical Development

    • Tenure: 0yrs
  • Justin Ford

    VP of Human Resources & Head of People

    • Tenure: 2.5yrs
  • Caryn McDowell (49yo)

    Senior VP

    • Tenure: 1.6yrs
    • Compensation: US$2.80m
  • Toby Schilke (44yo)

    CFO & Principal Accounting Officer

    • Tenure: 1.1yrs
    • Compensation: US$1.97m
  • Conor Gallagher

    Head of Medical Affairs & Aesthetics

    • Tenure: 1.6yrs
  • Taryn Conway

    Vice President of Marketing

    • Tenure: 0.7yrs

Board Members

  • Angus Russell (63yo)

    Independent Chairman

    • Tenure: 5.8yrs
    • Compensation: US$269.98k
  • Phyllis Gardner (68yo)

    Independent Director

    • Tenure: 13yrs
    • Compensation: US$233.01k
  • Bob Byrnes (74yo)

    Independent Director

    • Tenure: 15.3yrs
    • Compensation: US$247.26k
  • Mark Foley (54yo)

    President

    • Tenure: 0.2yrs
    • Compensation: US$243.01k
  • Jill Beraud (59yo)

    Director

    • Tenure: 0.5yrs
  • Phil Vickers (59yo)

    Independent Director

    • Tenure: 4.8yrs
    • Compensation: US$235.26k
  • Julian Gangolli (61yo)

    Independent Director

    • Tenure: 3.4yrs
    • Compensation: US$230.51k
  • Chris Nolet (62yo)

    Director

    • Tenure: 0.4yrs

Company Information

Revance Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Revance Therapeutics, Inc.
  • Ticker: RVNC
  • Exchange: NasdaqGM
  • Founded: 1999
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$908.933m
  • Shares outstanding: 45.11m
  • Website: https://www.revance.com

Number of Employees


Location

  • Revance Therapeutics, Inc.
  • 7555 Gateway Boulevard
  • Newark
  • California
  • 94560
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RVNCNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDFeb 2014
RTIDB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014

Biography

Revance Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development, manufacture, and commercialization of novel neuromodulators for various aesthetic and therapeutic indications ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/12/09 00:19
End of Day Share Price2019/12/06 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.